EAM Investors LLC lowered its holdings in shares of CONMED Co. (NASDAQ:CNMD) by 7.1% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 41,222 shares of the medical technology company’s stock after selling 3,135 shares during the period. EAM Investors LLC’s holdings in CONMED were worth $3,266,000 as of its most recent filing with the SEC.

Several other institutional investors have also bought and sold shares of the company. Robeco Institutional Asset Management B.V. bought a new stake in CONMED during the 2nd quarter worth $154,000. Harvest Fund Management Co. Ltd bought a new stake in CONMED during the 3rd quarter worth $168,000. Itau Unibanco Holding S.A. bought a new stake in CONMED during the 2nd quarter worth $165,000. Wendell David Associates Inc. bought a new stake in CONMED during the 3rd quarter worth $208,000. Finally, Hartford Investment Management Co. bought a new stake in CONMED during the 2nd quarter worth $203,000. 95.85% of the stock is owned by institutional investors.

In other CONMED news, VP Stanley W. Peters III sold 1,500 shares of the company’s stock in a transaction dated Friday, September 14th. The stock was sold at an average price of $80.43, for a total value of $120,645.00. Following the sale, the vice president now owns 1,496 shares in the company, valued at approximately $120,323.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Heather L. Cohen purchased 900 shares of CONMED stock in a transaction on Tuesday, November 6th. The stock was bought at an average price of $68.60 per share, for a total transaction of $61,740.00. The disclosure for this purchase can be found here. Insiders own 3.13% of the company’s stock.

A number of brokerages recently weighed in on CNMD. Zacks Investment Research upgraded CONMED from a “sell” rating to a “hold” rating in a research report on Wednesday, October 3rd. Leerink Swann boosted their price objective on CONMED from $76.00 to $81.00 and gave the stock a “market perform” rating in a research report on Thursday, August 30th. BidaskClub lowered CONMED from a “hold” rating to a “sell” rating in a research report on Friday, November 2nd. Finally, Needham & Company LLC boosted their price objective on CONMED from $73.00 to $83.00 and gave the stock a “buy” rating in a research report on Thursday, August 2nd. One analyst has rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company’s stock. CONMED has a consensus rating of “Hold” and a consensus target price of $81.50.

Shares of CNMD stock opened at $67.57 on Tuesday. The firm has a market cap of $1.93 billion, a P/E ratio of 32.05, a PEG ratio of 2.75 and a beta of 0.68. CONMED Co. has a twelve month low of $49.22 and a twelve month high of $83.49. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.27 and a current ratio of 2.20.

CONMED (NASDAQ:CNMD) last issued its quarterly earnings data on Thursday, November 1st. The medical technology company reported $0.46 earnings per share for the quarter, topping analysts’ consensus estimates of $0.45 by $0.01. CONMED had a return on equity of 9.51% and a net margin of 8.56%. The business had revenue of $202.30 million for the quarter, compared to analyst estimates of $198.51 million. During the same quarter in the previous year, the company posted $0.42 EPS. CONMED’s quarterly revenue was up 6.4% compared to the same quarter last year. Equities research analysts expect that CONMED Co. will post 2.17 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Monday, January 7th. Shareholders of record on Friday, December 14th will be given a $0.20 dividend. The ex-dividend date is Thursday, December 13th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 1.18%. CONMED’s dividend payout ratio (DPR) is presently 42.33%.

ILLEGAL ACTIVITY WARNING: “CONMED Co. (CNMD) Shares Sold by EAM Investors LLC” was published by Daily Political and is the property of of Daily Political. If you are reading this news story on another website, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The legal version of this news story can be read at https://www.dailypolitical.com/2018/11/20/conmed-co-cnmd-shares-sold-by-eam-investors-llc.html.

CONMED Profile

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for minimally invasive procedures in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers orthopedic surgery products, including sports medicine products comprising powered resection instruments, arthroscopes, reconstructive systems, tissue repair sets, and metal and bioabsorbable implants, as well as related disposable products and fluid management systems; powered surgical instruments for use in bone orthopedic, arthroscopic, oral/maxillofacial, podiatric, plastic, ENT, neurological, spinal, and cardiothoracic surgeries; sports biologics and tissue products; and surgical visualization products.

Featured Article: Can individual investors take part in an IPO?

Want to see what other hedge funds are holding CNMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CONMED Co. (NASDAQ:CNMD).

Institutional Ownership by Quarter for CONMED (NASDAQ:CNMD)

Receive News & Ratings for CONMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CONMED and related companies with MarketBeat.com's FREE daily email newsletter.